The Company is an industry leader in the development of human birth tissue donation programs. The Company partners with hospitals and physicians offices to provide human birth tissues for regenerative medicine, manufacturing of placental tissue allografts, and other innovative biologic wound care products.
Key Aspects
· Total revenue growth has increased by an impressive 79% from 2021
through the trailing twelve month (TTM) period ending July 31, 2024.
· The Company has established dependable partnerships with tissue banks,
which have facilitated scalable business growth and supported organic
expansion.
· The Company has distinguished itself in the industry by prioritizing the
quality of tissue recovery, the accuracy and completeness of donor charts,
and the timely delivery of tissue to end users.
· All contracts with tissue processors are recurring, and the Company's
exceptional service has resulted in a high rate of repeat business.
· Financials as of 4/25
REF-BN000055457
Ad#:2379263
